NASDAQ:ONCE - Spark Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $50.15 -0.74 (-1.45 %) (As of 02/21/2019 02:44 PM ET)Previous Close$50.89Today's Range$49.12 - $50.5852-Week Range$34.53 - $96.59Volume14,276 shsAverage Volume458,913 shsMarket Capitalization$1.89 billionP/E Ratio-23.78Dividend YieldN/ABeta2.06 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Receive ONCE News and Ratings via Email Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCE Previous Symbol CUSIPN/A Webwww.sparktx.com Phone888-772-7560Debt Debt-to-Equity Ratio0.09 Current Ratio10.71 Quick Ratio10.36Price-To-Earnings Trailing P/E Ratio-23.78 Forward P/E Ratio-11.83 P/E GrowthN/A Sales & Book Value Annual Sales$64.72 million Price / Sales29.25 Cash FlowN/A Price / Cash FlowN/A Book Value$13.88 per share Price / Book3.61Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-253,480,000.00 Net Margins-121.78% Return on Equity-14.66% Return on Assets-10.42%Miscellaneous Employees315 Outstanding Shares37,750,000Market Cap$1.89 billion OptionableOptionable Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($1.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.89. The biotechnology company had revenue of $13.15 million for the quarter, compared to analysts' expectations of $26.76 million. Spark Therapeutics had a negative return on equity of 14.66% and a negative net margin of 121.78%. The business's revenue for the quarter was up 47.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.63) earnings per share. View Spark Therapeutics' Earnings History. When is Spark Therapeutics' next earnings date? Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Spark Therapeutics. What price target have analysts set for ONCE? 20 brokerages have issued 12 month target prices for Spark Therapeutics' shares. Their forecasts range from $40.00 to $85.00. On average, they anticipate Spark Therapeutics' share price to reach $65.9474 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Price Targets for Spark Therapeutics. What is the consensus analysts' recommendation for Spark Therapeutics? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spark Therapeutics. What are Wall Street analysts saying about Spark Therapeutics stock? Here are some recent quotes from research analysts about Spark Therapeutics stock: 1. William Blair analysts commented, "We continue to anticipate an update from SPK-8011 with prophylactic steroid therapy to treat hemophilia A (expected by midyear) to be the next key catalyst for the company (for a review of the data presented at 2018 ASH, see our note: 2018 ASH Hemophilia Update; Durable Factor Expression, but 2019 Data Needed to Answer Questions)." (2/19/2019) 2. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (1/9/2019) 3. JPMorgan Chase & Co. analysts commented, "ONCE’s 3Q print encouragingly showed in line Luxturna sales of ~$9M, although a resetting of expectations around the SPK-8011 update at ASH overshadowed launch progress. Given the historical focus on FVIII levels, we aren’t surprised to see disappointment about the news that there will be no biomarker data for the high dose cohort at ASH (there will be clinical outcome data). Indeed, for some time we’ve gotten the sense that at least some investors may wait to see additional SPK-8011 FVIII activity data before re-engaging. That said, today’s update doesn’t fundamentally change the fact that ONCE continues to be a leader in the gene therapy space, with an active early-stage pipeline (2 new programs entering clinic in late- 2018/2019) and an update on SPK-7001 expected by YE18. Maintain Neutral." (11/7/2018) 4. Raymond James analysts commented, "We are maintaining our Outperform rating for shares of ONCE. This morning the E.U.’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of LUXTURNA for the treatment of vision loss due to inherited retinal dystrophy (IRD) caused by mutations in the retinal pigment epithelium- specific 65 kDa (RPE65) gene. Along with robust data from the company’s Phase III study that demonstrated safety, efficacy, and durability of response for up to three years, the company awaits a marketing authorization from the European Commission within two months to become the first gene therapy for a genetic disease approved in both the U.S. and E.U. With U.S." (9/21/2018) 5. Mizuho analysts commented, "We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts." (8/8/2018) Has Spark Therapeutics been receiving favorable news coverage? Media stories about ONCE stock have trended somewhat positive on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spark Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Spark Therapeutics' key competitors? Some companies that are related to Spark Therapeutics include bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Allogene Therapeutics (ALLO), Ablynx (ABLYF), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP) and Regenxbio (RGNX). What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Celgene (CELG), Exelixis (EXEL), AbbVie (ABBV), bluebird bio (BLUE), Amgen (AMGN) and Intel (INTC). Who are Spark Therapeutics' key executives? Spark Therapeutics' management team includes the folowing people: Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)Mr. Stephen W. Webster, Chief Financial Officer (Age 58)Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)Mr. Daniel R. Faga, Chief Bus. Officer (Age 39) When did Spark Therapeutics IPO? (ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. Who are Spark Therapeutics' major shareholders? Spark Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.23%), Partner Fund Management L.P. (5.78%), D. E. Shaw & Co. Inc. (2.69%), Casdin Capital LLC (2.23%), Great Point Partners LLC (1.67%) and Macquarie Group Ltd. (1.65%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics. Which major investors are selling Spark Therapeutics stock? ONCE stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Squarepoint Ops LLC, Lord Abbett & CO. LLC, Elk Creek Partners LLC, WS Management Lllp, TD Asset Management Inc., Bailard Inc. and Tekla Capital Management LLC. View Insider Buying and Selling for Spark Therapeutics. Which major investors are buying Spark Therapeutics stock? ONCE stock was bought by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., D. E. Shaw & Co. Inc., Great Point Partners LLC, Casdin Capital LLC, Dimensional Fund Advisors LP, Macquarie Group Ltd., BlackRock Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Spark Therapeutics. How do I buy shares of Spark Therapeutics? Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $50.21. How big of a company is Spark Therapeutics? Spark Therapeutics has a market capitalization of $1.90 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe. What is Spark Therapeutics' official website? The official website for Spark Therapeutics is http://www.sparktx.com. How can I contact Spark Therapeutics? Spark Therapeutics' mailing address is 3737 Market Street Suite 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected] MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 450 (Vote Outperform)Underperform Votes: 351 (Vote Underperform)Total Votes: 801MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR?